PTGS2 and non-small cell lung carcinoma: The COX-2 −1195A allele was also associated with a poor response to vinorelbine-based chemotherapy in patients with NSCLC.26 Therefore, it was the rationale that a more intensive treatment, such as a combination of chemoradiation therapy and COX-2 inhibition, could improve the survival in patients with the unfavorable COX-2 −1195dupA genotype.